In women, medroxyprogesterone acetate (MPA) is the most commonly used progestin component of hormone therapy (HT). In vitro, MPA negatively impacts markers of neuronal health and exacerbates experimentally-induced neurotoxicity. There is in vitro evidence that these factors are driven by GABAergic and neurotrophic systems. Whether these effects translate to a negative impact on brain function has not been tested in vivo, clinically or preclinically. Here we evaluate the mnemonic and neurobiological effects of MPA in the surgically menopausal rat. Aged ovariectomized (OVX) rats were given subcutaneous vehicle, natural progesterone, low-dose MPA or high-dose MPA. Multiple cognitive domains were analyzed via the water radial-arm maze (WRAM) and Morris maze (MM). Cognitive brain regions were assayed for changes in the GABAergic system by evaluating GAD protein, the synthesizing enzyme for GABA, and neurotrophins. On the WRAM, both progestin types impaired learning. Further, high-dose MPA impaired delayed memory retention on the WRAM, and exacerbated overnight forgetting on the MM. While neurotrophins were not affected by progesterone or MPA treatment, both progestin types altered GAD levels. MPA significantly and progesterone marginally decreased GAD levels in the hippocampus, and both MPA and progesterone significantly increased GAD levels in the entorhinal cortex. These findings suggest that MPA, the most commonly used progestin in HT, is detrimental to learning and two types of memory, and modulates the GABAergic system in cognitive brain regions, in aged surgically menopausal rats. These findings, combined with in vitro evidence that MPA is detrimental to neuronal health, indicates that MPA has negative effects for brain health and function.
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Introduction
By the year 2050 there will be an estimated 90 million people in the United States who are over the age of 65, and over half of these individuals will be postmenopausal women (US Census Bureau, 2007) . Menopause, occurring typically in the fifth decade of life, is characterized by loss of ovary-derived circulating hormones, including estrogen and progesterone (Timaras, Quay, & Vernadakis, 1995) . Menopause-induced hormone loss has been linked to many symptoms that affect quality of life in women including hot flashes, urogenital atrophy and memory decline (Freedman, 2002; Nappi et al., 1999; Sherwin, 1988) . Hormone therapy (HT) is given to women to attenuate menopause-induced symptoms. Premarin, a complex combination of horse-derived estrogens, is the most widely used estrogenic component of HT (Hersh, Stefanick, & Stafford, 2004) . Women with a uterus that are taking estrogens must include a progestin in their regimen because of increased risk of endometrial hyperplasia associated with unopposed estrogen treatment (Smith, Prentice, Thompson, & Herrmann, 1975; Ziel & Finkle, 1975) . Prempro (Premarin + medroxyprogesterone acetate; MPA) is the most widely prescribed progestincontaining HT in the United States, with an estimated 20 million prescriptions written per year within the last decade (Hersh et al., 2004) . Further, over 10 million women in the United States have been prescribed MPA as the injectable contraceptive Depo Provera (Mosher, Martinez, Chandra, Abma, & Willson, 2004) . Thus, MPA is widely clinically utilized.
Several clinical studies in menopausal and postmenopausal women have demonstrated positive effects of estrogen-containing HT on memory and cognition (Campbell & Whitehead, 1977; Duka, Tasker, & McGowan, 2000; Kantor, Michael, & Shore, 1973; Ohkura et al., 1995; Phillips & Sherwin, 1992; Sherwin, 1988; Wolf et al., 
